PET/MRI of the breast |
| |
| Affiliation: | 1. Department of Radiology and Nuclear Medicine, Maastricht University Medical Center+, Maastricht, The Netherlands;2. Department of Surgery, Maastricht University Medical Center+, Maastricht, The Netherlands;3. GROW – School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, The Netherlands;4. Department of Surgery, Catharina Hospital, Eindhoven, The Netherlands;5. Department of Epidemiology, Maastricht University Medical Center+, Maastricht, The Netherlands;6. Department of Pathology, Zuyderland Hospital, Heerlen, The Netherlands;7. Department of Radiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands;1. Servicio de Medicina Nuclear, Instituto de Investigación Sanitaria, Hospital Clínico San Carlos, Madrid, España;2. Servicio de Medicina Nuclear, Hospital Universitario HM Puerta del Sur, Móstoles, Madrid, España;3. Servicio de Radiología, Hospital Universitario HM Puerta del Sur, Móstoles, Madrid, España;1. Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan;2. Department of Breast Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan;1. University of Tuebingen, Department of Radiology, Diagnostic and Interventional Radiology, Germany;2. University of Tuebingen, Department of Radiology, Diagnostic and Interventional Neuroradiology, Germany;3. University of Tuebingen, Department of Radiology, Nuclear Medicine, Germany;2. Service de Radiologie, Hôpitaux Universitaires de Genève, rue Gabrielle-Perret-Gentil, Genève, Switzerland;3. Service de Radio-Oncologie, Hôpitaux Universitaires de Genève, rue Gabrielle-Perret-Gentil, Genève, Switzerland;4. Servei de Radio-Oncologia, Instituto Oncológico Teknon, Barcelona, Spain |
| |
| Abstract: | The future clinical use of the combination of positron emission tomography (PET) with 2-Fluoro[F-18]-2-Deoxy-d-Glucose (FDG)and MRI is still unclear. If a patient requires a PET and breast DCE-MRI for staging purposes, both scans can be done in the same visit. In the breast, DCE-MRI is better at lesion detection (sensitivity), margin evaluation, and has a higher specificity than CT. The potential for multiparametric qualitative and quantitative imaging is also an advantage of PET/MRI which provides opportunity to improve tumor characterization and may ultimately lead to outcome prediction. This review discusses technical and clinical aspects of this emerging technology in breast cancer patients. |
| |
| Keywords: | PET/MRI Breast cancer PET/CT Multiparametric MRI |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
